76,967 Shares in Kenvue Inc. (NYSE:KVUE) Purchased by Proficio Capital Partners LLC

Proficio Capital Partners LLC acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 76,967 shares of the company’s stock, valued at approximately $1,643,000.

Several other hedge funds have also modified their holdings of KVUE. Grove Bank & Trust grew its position in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at about $29,000. SRS Capital Advisors Inc. boosted its holdings in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after acquiring an additional 571 shares during the period. Fortitude Family Office LLC boosted its stake in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc grew its holdings in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $23.49 on Thursday. The business’s 50-day moving average price is $21.98 and its two-hundred day moving average price is $22.42. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a market capitalization of $44.89 billion, a P/E ratio of 44.31, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Analyst Ratings Changes

Several equities research analysts have issued reports on KVUE shares. Citigroup dropped their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Piper Sandler upped their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Canaccord Genuity Group boosted their price objective on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Finally, Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.